NR3C1 and post-traumatic stress disorder: To evaluate the effects of CRHR2 agonist administration on the development of PTSD-like manifestations in the SPS animal model, we measured the mRNA levels of CRH, CRHR1, CRHR2, GR, and FKBP5 in the brain regions involved in stress recovery and fear and anxiety processing, i.e., the BNST, Amy, and PVN.